pS2 and Hormone Therapy Response in Breast Cancer
Author Information
Author(s): F. Spyratos, C. Andrieu, K. Hacenel, P. Chambon, M.C. Rio
Primary Institution: Centre Rene Huguenin
Hypothesis
Does pS2 status predict the response to hormone therapy in breast cancer patients?
Conclusion
The study found that pS2 positivity is associated with longer overall survival and better response to hormone therapy in breast cancer patients.
Supporting Evidence
- pS2 status correlated positively with oestradiol and progesterone receptors.
- pS2 positivity was associated with longer overall survival.
- Patients receiving hormone therapy showed a predictive response based on pS2 status.
Takeaway
This study shows that a protein called pS2 can help doctors understand which breast cancer patients will do better with hormone treatments.
Methodology
The study reviewed 319 primary breast tumors for pS2 content and evaluated its prognostic and predictive value for hormone therapy response.
Limitations
The study is retrospective and may not account for all variables affecting patient outcomes.
Participant Demographics
Mean age of participants was 55 years, with a range from 30 to 86 years.
Statistical Information
P-Value
0.01
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website